Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis

Autor: Hoda Khallaghi, Sorayya Kakhi, Amir Azarpazhooh, Elias Orouji, Mahmoud Reza Azarpazhooh, Naghmeh Mokhber, Bita Khorram, Morteza Modares Gharavi
Rok vydání: 2015
Předmět:
Zdroj: Psychiatry and Clinical Neurosciences. 69:649-657
ISSN: 1323-1316
Popis: Aims The aim of this study was to evaluate the effect of various disease-modifying therapies (DMT) on quality of life in multiple sclerosis (MS). Methods This was a three-arm parallel study with balanced randomization in which 90 newly diagnosed, definite MS subjects referred to Ghaem Medical Center, Mashhad, Iran were enrolled between 2006 and 2009. Patients were randomly allocated into three DMT groups: Avonex, Rebif and Betaferon. Health-related quality of life was assessed in MS patients at baseline and 12 months after treatment with DMT using the MS Quality of Life-54 questionnaire. Results Both mental and physical health scores improved within all three treatment groups after 12 months of treatment; however, this increase was only significant in the mental health composite in the Betaferon group (P = 0.024). Betaferon had the highest mental health score change (14.04) while this change was 7.26 for Avonex (P = 0.031) and 5.08 for Rebif (P = 0.017). A physical health composite score comparison among the three treatment groups revealed no significant results. Conclusions With a positive impact of DMT on mental and physical dimensions of QOL in MS patients, initiation of treatment soon after diagnosis is recommended. In MS patients with more mental issues and fewer physical disabilities, Betaferon might be considered as a better choice of treatment.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje